Corrigendum to ‘Central Nervous System Progression in Patients Receiving ALK-Targeted Central Nervous System–Penetrable Tyrosine Kinase Inhibitors: Treatment Patterns and Outcomes’ [JTO Clinical and Research Reports 6 (2025) 100914]

Read full text Summarise with VIRAT
Authors: Surbhi Singhal, Caressa Hui, Joel W. Neal, Seema Nagpal, Mohana Roy, Millie Snigdha Das, Kavitha J. Ramchandran, Erqi Liu Pollom, Giovanni Selvaggi, Heather A. Wakelee, Nathaniel James Myall
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

The authors regret that an error occurred in the Abstract and in the Dose Escalation of Alectinib portion of the Results in the published article, “Central Nervous System Progression in Patients Receiving ALK-Targeted Central Nervous System–Penetrable Tyrosine Kinase Inhibitors: Treatment Patterns and Outcomes” (Singhal S et al, JTO Clin Res Rep. 2025 Oct 3;6(12):100914).

Fields of Study & Subjects

Lung Cancer Treatments and Mutations Brain Metastases and Treatment Lung Cancer Diagnosis and Treatment

Publication details

Journal / source
JTO Clinical and Research Reports
Volume
7
Issue
6
Pages
100992–100992
Publication date
20 March 2026
Language
EN